There is hardly any day without CRISPR news. February starts with researchers correcting abnormalities associated with Duchenne muscular dystrophy (Science Advances) and performing allele-specific editing in blind mice (bioRxiv, forthcoming in The CRISPR Journal). A repechage from January also: how to get pluripotent stem cells by CRISPRing just one gene (Cell Stem Cell).
Reversing three genetic diseases in the animal model without even changing a single DNA letter. A Salk Institute team did it by bringing together two of biomedicine’s hottest trends. One is the CRISPR technique, which edits target genes through a programmable molecular machine named Cas9. The other is epigenetics, i.e., the study of chemical modifications that switch genes on and off without altering their sequence. It’s called epigenetic editing, because corrections are precise as in manuscript revision and occur at a level that is over (epi- in Greek) genetics. Continue reading